COVAX no-fault compensation program for AMC eligible economies (the “Program”)

Extension of the Program’s Delivery Date

June 2022
Purpose and Objectives of the Program

- Provide fair no-fault lump-sum compensation in full and final settlement of any claims to individuals who suffer SAE resulting in permanent impairment or death associated with a COVID-19 vaccine *earmarked for delivery* through the COVAX Facility for use in any Gavi AMC eligible economy (AMC 92) until 30 June 2022 (proposed extension until to 30 June 2023), or the administration of such a vaccine (e.g., Programmatic errors)
  - “Earmarked for delivery” means a purchase order is accepted or a donation agreement is in place

- Inspire a high level of trust: the Program is managed by an independent claims' administrator with over 30 years’ relevant experience with representation in all AMC92

- Be equitable, robust, fast and transparent: The Program is based on detailed publicly available Protocol and forms, allows applicants ample time to submit the required documents, and provides a fair level of compensation
Extension of the Delivery Date to 30 June 2023

▪ The COVAX Conveners have, in principle, agreed to extend the Program’s *earmarking for delivery deadline* (the “**Delivery Date**”) from 30 June 2022 to 30 June 2023. Such extension does not change the Program’s per Vaccine scope of coverage end point (SCE) or the Program’s originally foreseen end-date of 30 June 2027;

▪ Agreement to extend the Delivery Date has been reached with the Program’s insurers and administrator on this basis;

▪ The COVAX Conveners are currently in the process of negotiating and finalizing the various documentation needed to implement the extension of the Program’s Delivery Date.
1. Vaccines must be earmarked for delivery on or prior to 30 June 2023 (extended Delivery Date).

2. Vaccines so earmarked must be administered prior to their SCE (2 years after vaccine was first put into circulation in any country).

3. Applications may be filed up to the end of the reporting period (3 years after the SCE) and, in any event, no later than the Program’s end date of 30 June 2027.

4. SAE resulting in death or permanent impairment must have arisen following administration of the COVAX-distributed vaccine.
THANK YOU